[go: up one dir, main page]

PE20080834A1 - Derivados de eter diarilico antagonistas de receptores opioides - Google Patents

Derivados de eter diarilico antagonistas de receptores opioides

Info

Publication number
PE20080834A1
PE20080834A1 PE2007001196A PE2007001196A PE20080834A1 PE 20080834 A1 PE20080834 A1 PE 20080834A1 PE 2007001196 A PE2007001196 A PE 2007001196A PE 2007001196 A PE2007001196 A PE 2007001196A PE 20080834 A1 PE20080834 A1 PE 20080834A1
Authority
PE
Peru
Prior art keywords
methyl
phenoxy
diarylic
opioid receptors
benzamide
Prior art date
Application number
PE2007001196A
Other languages
English (en)
Inventor
Roger Benjamin Ruggeri
George Tetteh Magnus-Aryitey
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38963180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080834(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20080834A1 publication Critical patent/PE20080834A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)

Abstract

REFERIDA A UN DERIVADO DE ETER DIARILICO DE FORMULA (I), DONDE R1 ES H O METILO; R2 ES ALQUILO C3-C10, CICLOALQUILO DE 5 A 6 MIEMBROS OPCIONALMENTE CONDENSADO A UN ANILLO DE BENCENO O (CH(R))m(CH2)n-A, EN EL QUE m ES 1; n ES 0, 1 O 2; R ES H, METILO O ETILO; A ES ALCOXI C1-C4, FENOXI, FENILO, ENTRE OTROS; R4 ES H O HALOGENO; R5 ES H O HALOGENO. SON COMPUESTOS PREFERIDOS: 4-{2-FLUORO-4-[(3-METIL-BUTILAMINO)-METIL]-FENOXI}-2-HIDROXI-BENZAMIDA, 4-{2,6-DIFLUORO-4-[(3-METIL-BUTILAMINO)-METIL]-FENOXI}-2-HIDROXI-BENZAMIDA, 4-[2-FLUORO-4-(INDAN-2-ILAMINOMETIL)-FENOXI]-2-HIDROXI-BENZAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DE LOS RECEPTORES OPIOIDES MU, KAPPA Y DELTA Y SON UTILES EN EL TRATAMIENTO DE LA OBESIDAD Y ENFERMEDADES RELACIONADAS
PE2007001196A 2006-09-08 2007-09-06 Derivados de eter diarilico antagonistas de receptores opioides PE20080834A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82494406P 2006-09-08 2006-09-08

Publications (1)

Publication Number Publication Date
PE20080834A1 true PE20080834A1 (es) 2008-07-19

Family

ID=38963180

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001196A PE20080834A1 (es) 2006-09-08 2007-09-06 Derivados de eter diarilico antagonistas de receptores opioides

Country Status (17)

Country Link
US (1) US7618996B2 (es)
EP (1) EP2064199A1 (es)
JP (1) JP2010502688A (es)
KR (1) KR20090051778A (es)
CN (1) CN101511808A (es)
AR (1) AR062679A1 (es)
AU (1) AU2007297285A1 (es)
CA (1) CA2662766C (es)
CL (1) CL2007002611A1 (es)
GT (1) GT200700075A (es)
IL (1) IL197154A0 (es)
MX (1) MX2009002527A (es)
NO (1) NO20091052L (es)
PE (1) PE20080834A1 (es)
TW (1) TW200831074A (es)
UY (1) UY30577A1 (es)
WO (1) WO2008032156A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010527980A (ja) 2007-05-22 2010-08-19 プロシディオン・リミテッド 代謝障害を治療するための二環状アリールおよびヘテロアリール化合物
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8063247B2 (en) 2007-09-07 2011-11-22 Prosidion Limited Bicyclic aryl and heteroaryl receptor modulators
CA2713025C (en) 2008-01-22 2012-12-04 Eli Lilly And Company Kappa selective opioid receptor antagonist
WO2011053706A1 (en) * 2009-10-30 2011-05-05 Janssen Pharmaceutica Nv 4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators
TW201343629A (zh) * 2012-01-31 2013-11-01 Lilly Co Eli 可作為mogat-2抑制劑之新穎芐磺醯胺衍生物
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
CN111925325B (zh) * 2020-02-17 2021-12-17 浙江大学 一种二芳香醚类化合物的合成方法
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
KR20240152410A (ko) 2022-03-07 2024-10-21 얀센 파마슈티칼즈, 인코포레이티드 아티카프란트를 포함하는 조성물
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2171839T3 (es) 1996-09-05 2002-09-16 Lilly Co Eli Analogos de carbazol como agonistas adrenergicos selectivos de beta3.
CO5011072A1 (es) 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
WO2002006276A1 (en) 2000-07-13 2002-01-24 Eli Lilly And Company Beta3 adrenergic agonists
US7507767B2 (en) * 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
ATE308522T1 (de) 2002-05-30 2005-11-15 Lilly Co Eli Opioidrezeptorantagonisten
US20050267114A1 (en) * 2002-09-18 2005-12-01 Yoshikazu Takaoka Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient
UA80437C2 (en) 2002-09-19 2007-09-25 Lilly Co Eli Diaryl ethers as opioid receptor antagonist
AU2004220112A1 (en) 2003-03-07 2004-09-23 Eli Lilly And Company 6-substituted nicotinamide derivatives as opioid receptor antagonists
MXPA05009367A (es) * 2003-03-07 2005-11-04 Lilly Co Eli Antagonistas del receptor opioide.
BRPI0417156A (pt) 2003-12-12 2007-03-06 Lilly Co Eli composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso
WO2005066164A1 (en) * 2003-12-22 2005-07-21 Eli Lilly And Company Opioid receptor antagonists
US7381750B2 (en) 2004-03-12 2008-06-03 Eli Lilly And Company Amino-phenoxymethyl-benzamide opioid receptor antagonists
ES2308471T3 (es) 2004-03-12 2008-12-01 Eli Lilly And Company Antagonistas de receptores de opioides.
ATE545413T1 (de) 2004-03-15 2012-03-15 Lilly Co Eli Antagonisten des opioidrezeptors
WO2007047397A2 (en) 2005-10-13 2007-04-26 Smithkline Beecham Corporation Phenol ethers as modulators of the opioid receptors

Also Published As

Publication number Publication date
CN101511808A (zh) 2009-08-19
KR20090051778A (ko) 2009-05-22
CA2662766C (en) 2011-08-09
EP2064199A1 (en) 2009-06-03
MX2009002527A (es) 2009-03-20
JP2010502688A (ja) 2010-01-28
TW200831074A (en) 2008-08-01
US20080070887A1 (en) 2008-03-20
WO2008032156A1 (en) 2008-03-20
GT200700075A (es) 2008-09-19
CA2662766A1 (en) 2008-03-20
AR062679A1 (es) 2008-11-26
AU2007297285A1 (en) 2008-03-20
US7618996B2 (en) 2009-11-17
NO20091052L (no) 2009-04-06
UY30577A1 (es) 2008-05-02
IL197154A0 (en) 2009-11-18
CL2007002611A1 (es) 2008-03-14

Similar Documents

Publication Publication Date Title
PE20080834A1 (es) Derivados de eter diarilico antagonistas de receptores opioides
AR062886A1 (es) Compuestos de tiazol pirazolopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
AR037682A1 (es) Derivados de acetileno que tienen actividad antagonista para receptores glutamato metabotropico humanos, composicion farmaceutica, una combinacion y el uso de dichos derivados para la fabricacion de composiciones farmaceuticas
ECSP088120A (es) Derivados de piridazinona como agonistas del receptorde la hormona tiroidea
PE20060693A1 (es) Nuevos derivados de trifluorometansulfonanilida oxamida eter
EA200970342A1 (ru) Антагонисты рецептора глюкагона, композиции, содержащие такие соединения, и способы применения
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
AR060974A1 (es) Compuesto de 4-piridinona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende, proceso para su preparacion y proceso para la preparacion de un compuesto intermediario de utilidad en el anterior
PE20131463A1 (es) Piperidino-dihidrotienopirimidinas sustituidas
UY28014A1 (es) Compuestos quimicos
UY28369A1 (es) Agentes terapéuticos
EA200870472A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
PE20020476A1 (es) Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos
AR061815A1 (es) Compuesto de oxo-prolinamida composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento
PA8545301A1 (es) Nuevos derivados de quinolina
CL2004000382A1 (es) Tetrahidroisoquinolinas sustituidas, proceso de preparacion, y composicion farmaceutica, utiles en el tratamiento y prevencion de estados patologicos que se alivian con un agonista de 5-ht6.
PE20091092A1 (es) Compuestos heterociclicos como inhibidores de la via hedgehog
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
AR049578A1 (es) Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas
PE20061013A1 (es) Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias
BRPI0409454A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com o receptor de glucagon e sua utilização
PE20091431A1 (es) Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica
PE20040907A1 (es) Derivados de anilinopirazol
UY29169A1 (es) Derivados de 2-amido-4 feniltiazol, su preparacion y su aplicacion en terapeutica
PE20061348A1 (es) DERIVADOS DEL ACIDO PIRMIDINCARBOXILICO COMO MODULADORES DE PPAR-alfa

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed